EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance

Hana Q Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A Macha, Ammira S Al-Shabeeb Akil, Ajaz A Bhat

Translational Oncology · 2024-01 · 39 · 101821

DOI: 10.1016/j.tranon.2023.101821 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2024-01. Verfasst von Hana Q Sadida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Precision Medicine in Diabetes, Obesity and Cancer, Department of Population Genetics, Sidra Medicine, Doha 26999, Qatar. Die Arbeit wurde bisher 154-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Qatar National Library.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer heterogeneity and drug resistance remain pivotal obstacles in effective cancer treatment and management. One major contributor to these challenges is epigenetic modifications - gene regulation that does not involve changes to the DNA sequence itself but significantly impacts gene expression. As we elucidate these phenomena, we underscore the pivotal role of epigenetic modifications in regulating gene expression, contributing to cellular diversity, and driving adaptive changes that can instigate therapeutic resistance. This review dissects essential epigenetic modifications - DNA methylation, histone modifications, and chromatin remodeling - illustrating their significant yet complex contributions to cancer biology. While these changes offer potential avenues for therapeutic intervention due to their reversible nature, the interplay of epigenetic and genetic changes in cancer cells presents unique challenges that must be addressed to harness their full potential. By critically analyzing the current research landscape, we identify knowledge gaps and propose future research directions, exploring the potential of epigenetic therapies and discussing the obstacles in translating these concepts into effective treatments. This comprehensive review aims to stimulate further research and aid in developing innovative, patient-centered cancer therapies. Understanding the role of epigenetic modifications in cancer heterogeneity and drug resistance is critical for scientific advancement and paves the way towards improving patient outcomes in the fight against this formidable disease.

Schlagwörter

Stichwörter der Autor:innen

Cancer heterogeneityChromatin remodelingDNA methylationDrug resistanceEpigenetic modificationsEpigenetic therapiesGene expression regulationHistone modifications

Autor:innen und Institutionen

  • Laboratory of Precision Medicine in Diabetes, Obesity and Cancer, Department of Population Genetics, Sidra Medicine, Doha 26999, Qatar.
  • Laboratory of Genomic Medicine, Department of Population Genetics, Sidra Medicine, Doha 26999, Qatar.
  • Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Jammu & Kashmir, India.
  • Laboratory of Precision Medicine in Diabetes, Obesity and Cancer, Department of Population Genetics, Sidra Medicine, Doha 26999, Qatar. Electronic address: aakil@sidra.org.
  • Laboratory of Precision Medicine in Diabetes, Obesity and Cancer, Department of Population Genetics, Sidra Medicine, Doha 26999, Qatar. Electronic address: abhat@sidra.org.

Förderung

  • Qatar National Library

Zitieren

APA

Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A., & Bhat, A. A. (2024). Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Translational Oncology, 39, 101821. https://doi.org/10.1016/j.tranon.2023.101821

Vancouver

Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil ASA, et al. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Translational Oncology. 2024;39:101821. doi:10.1016/j.tranon.2023.101821

BibTeX
@article{Sadida2024,
  author = {Sadida, Hana Q and Abdulla, Alanoud and Marzooqi, Sara Al and Hashem, Sheema and Macha, Muzafar A and Akil, Ammira S Al-Shabeeb and Bhat, Ajaz A},
  title = {Epigenetic modifications: Key players in cancer heterogeneity and drug resistance},
  journal = {Translational Oncology},
  year = {2024},
  volume = {39},
  pages = {101821},
  doi = {10.1016/j.tranon.2023.101821}
}
Kostenlos starten →